1. Adimab, LLC (12 from 48 patents)

2. Five Prime Therapeutics, Inc. (7 from 72 patents)

3. Genetics Institute, Inc. (6 from 389 patents)

4. Eli Lilly and Company (5 from 4,447 patents)

5. Novartis Ag (5 from 3,923 patents)

6. Dana-Farber-Cancer Institute Inc. (5 from 1,210 patents)

7. Children's Medical Center Corporation (5 from 1,038 patents)

8. Pdl Biopharma, Inc. (5 from 20 patents)

9. Ajinomoto Co., Ltd. (4 from 1,929 patents)

10. Washington University (3 from 1,587 patents)

11. Mochida Pharmaceutical Co., Ltd. (2 from 229 patents)

12. Protein Design Labs, Inc. (2 from 29 patents)

13. Hoffmann-La Roche Inc. (1 from 4,948 patents)

14. Teijin Limited (1 from 1,588 patents)

15. Progenics Pharmaceuticals, Inc. (1 from 69 patents)

1. 12018403 - Antibody libraries

2. 11891446 - Highly potent antibodies binding to death receptor 5

3. 11542330 - Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use

4. 11186646 - Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

5. 11155620 - Method of detecting TIM-3 using antibody molecules to TIM-3

6. 11008383 - Rationally designed, synthetic antibody libraries and uses therefor

7. 11008568 - Rationally designed, synthetic antibody libraries and uses therefor

8. 10981990 - Antibody molecules to TIM-3 and uses thereof

9. 10941204 - Highly potent antibodies binding to death receptor 4

10. 10889811 - Antibody libraries

11. 10787500 - Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species

12. 10689448 - Monoclonal antibodies to fibroblast growth factor receptor 2

13. 10562970 - Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

14. 10472419 - Antibody molecules to TIM-3 and uses thereof

15. 10196635 - Rationally designed, synthetic antibody libraries and uses therefor